Carrier protein influences immunodominance of a known epitope: implication in peptide vaccine design

A mimotope attached to an ITIM-SHP-1 interaction inhibitory peptide boosts immune response and efficacy

Antigen binding to the B-cell receptor initiates a downstream signalling pathway that contains both stimulatory and damping components. A malarial parasite-derived conformation-constrained peptide was conjugated to a signal-damping pathway inhibitor. Mice immunized with this antigen produced higher antibody levels which delayed parasitemia. This represents a new approach to antigen design.

Incorporation of a Novel CD4+ Helper Epitope Identified from Aquifex aeolicus Enhances Humoral Responses Induced by DNA and Protein Vaccinations

CD4+ T cells play an important role in the maturation of the antibody responses. Conjugation of identified CD4+ T cell helper epitope to the target antigen has been developed as a strategy to enhance vaccine-induced humoral immunity. In this work, we reported the identification of a novel HLA-IAb helper epitope LS-3 from Aquifex aeolicus. In silico analysis predicted this epitope to have high binding affinity to common human HLA alleles and have complementary binding coverage to the established PADRE epitope. Introduction of HLA-IAb knockout mutations to the LS-3 epitope significantly attenuated humoral responses induced by a vaccine containing this epitope. Finally, engineered fusion of the epitope to a model antigen, influenza hemagglutinin, significantly improved both binding and hemagglutination inhibition antibody responses in mice receiving DNA or protein vaccines. In summary, LS-3 and additional identified CD4+ helper epitopes may be further explored to improve vaccine responses in translational studies.

•

Identification of a novel CD4+ helper epitope, LS-3, from Aquifex aeolicus

•

In silico analysis predicts high binding affinity of LS-3 to human HLA-DR alleles

•

Fusing LS-3 to antigen enhances humoral response by vaccinations

Immune response characterization and vaccine potential of a recombinant chimera comprising B-cell epitope of Aeromonas hydrophila outer membrane protein C and LTB

Aeromonas hydrophila is one of the most virulent fish pathogens, causing colossal economic losses to the aquaculture industry annually. The absence of a safe and effective vaccine makes it very difficult to control this infection. Outer membrane proteins have been widely illustrated to confer protective immunity against a broad spectrum of gram negative bacteria. In the current study, we have analyzed the ability of B-cell epitopes of A. hydrophila's outer membrane protein C (OmpC) to confer protection against bacterial virulence. Bioinformatic algorithms were used to predict linear B-cell epitopes of OmpC and the corresponding nucleotide sequences were cloned in translational fusion with heat labile enterotoxin B subunit (LTB) of E. coli. Of the three recombinant LTB.epitope fusion proteins evaluated, antisera against the fusion protein comprising the epitope stretch of 143-175 amino acids gave maximum cross reactivity with the parent protein OmpC. The anti-fusion protein antisera contained both OmpC- and LTB-specific antibodies. The fusion proteins' LTB moiety retained its ability to bind to the GM₁ ganglioside receptor, an essential requirement for its adjuvanicity. Antibody isotyping, cytokine ELISA, and cytokine array analysis revealed a Th2 skewed type immune response along with the presence of some relevant Th17 and Th1 cytokines involved in conferring protective immunity. Surface exposure of the epitope_143-175 on live A. hydrophila membrane was investigated and validated using bacterial agglutination and flow cytometry analysis using anti-fusion protein antisera. Our results strongly support the potential of B-cell epitope_143-175 of OmpC of A. hydrophila, in fusion with the LTB, as an effective and promising vaccine candidate against this bacterium.

Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera

Plasmodium vivax is the most widespread species of Plasmodium, causing up to 50% of the malaria cases occurring outside sub-Saharan Africa. An effective vaccine is essential for successful control and potential eradication. A well-characterized vaccine candidate is the circumsporozoite protein (CSP). Preclinical and clinical trials have shown that both antibodies and cellular immune responses have been correlated with protection induced by immunization with CSP. On the basis of our reported approach of developing chimeric Plasmodium yoelii proteins to enhance protective efficacy, we designed PvRMC-CSP, a recombinant chimeric protein based on the P. vivax CSP (PvCSP). In this engineered protein, regions of the PvCSP predicted to contain human T cell epitopes were genetically fused to an immunodominant B cell epitope derived from the N-terminal region I and to repeat sequences representing the two types of PvCSP repeats. The chimeric protein was expressed in soluble form with high yield. As the immune response to PvCSP has been reported to be genetically restricted in the murine model, we tested the immunogenicity of PvRMC-CSP in groups of six inbred strains of mice. PvRMC-CSP was able to induce robust antibody responses in all the mouse strains tested. Synthetic peptides representing the allelic forms of the P. vivax CSP were also recognized to a similar extent regardless of the mouse strain. Furthermore, the immunization regimen induced high frequencies of multifunctional CD4(+) and CD8(+) PvRMC-CSP-specific T cells. The depth and breadth of the immune responses elicited suggest that immunization with PvRMC-CSP can circumvent the genetic restriction of the immune response to P. vivax CSP. Interestingly, PvRMC-CSP was also recognized by naturally acquired antibodies from individuals living in areas where malaria is endemic. These features make PvRMC-CSP a promising vaccine candidate for further development.

Study of binding interactions between MPT63 protein and Au nanocluster

Binding between AuNC andMycobacterium tuberculosisderived protein.